MedTrace Logo

Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors

NCT03366103 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2023-10-17

Study results available
· View outcomes & findings →

Summary

This phase I/II trial studies the best dose and side effects of navitoclax and how well it works when given together with vistusertib in treating patients with small cell lung cancer and solid tumors that have come back (relapsed). Drugs used in chemotherapy, such as navitoclax, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Vistusertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving navitoclax and vistusertib may work better than navitoclax alone in treating patients with small cell lung cancer and solid tumors.

Conditions

  • Metastatic Malignant Solid Neoplasm
  • Recurrent Lung Small Cell Carcinoma
  • Recurrent Malignant Solid Neoplasm
  • Refractory Malignant Solid Neoplasm
  • Stage III Lung Small Cell Carcinoma, by American Joint Committee on Cancer (AJCC) v7
  • Stage IIIA Lung Small Cell Carcinoma AJCC v7
  • Stage IIIB Lung Small Cell Carcinoma AJCC v7
  • Stage IV Lung Small Cell Carcinoma AJCC v7
  • Unresectable Solid Neoplasm

Interventions

BIOLOGICAL

Navitoclax

Given PO

DRUG

Vistusertib

Given PO

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Christine L Hann · JHU Sidney Kimmel Comprehensive Cancer Center LAO

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-20
Primary Completion
2021-07-28
Completion
2022-09-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03366103 on ClinicalTrials.gov